NeoStem's Progenitor Cell Therapy Enters Deal for Cell Therapy Manufacturing Services
NeoStem, Inc. (NYSE: NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1^c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.